AN2 Therapeutics, Inc. (ANTX)
USD 1.31
(-2.24%)
USD 1.31
(-2.24%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Cost of Revenue | - | 77 Thousand | - | - | - |
| Gross Profit | - | -77 Thousand | - | - | - |
| Operating Expenses | 69.63 Million | 42.26 Million | 21.57 Million | 7.28 Million | 5.17 Million |
| Selling, General and Administrative Expenses | 14.76 Million | 12.75 Million | 4.66 Million | 1.26 Million | 289 Thousand |
| Research and Development Expenses | 54.87 Million | 29.51 Million | 16.9 Million | 6.01 Million | 4.88 Million |
| Other Expenses | - | -45 Thousand | -38 Thousand | -6.32 Million | - |
| Cost and Expenses | 69.63 Million | 42.26 Million | 21.57 Million | 7.28 Million | 5.17 Million |
| Operating Income | -69.63 Million | -42.26 Million | -21.57 Million | -7.28 Million | -5.17 Million |
| Interest Expense | - | 514 Thousand | - | - | - |
| Income Tax Expense | - | 514 Thousand | -69 Thousand | -3000.00 | -31.06 Thousand |
| Earnings before Tax | -64.73 Million | -40.95 Million | -21.54 Million | -13.6 Million | -5.63 Million |
| Net Income | -64.73 Million | -41.47 Million | -21.47 Million | -13.6 Million | -5.63 Million |
| Earnings Per Share Basic | -2.74 | -2.14 | -1.15 | -0.73 | -0.30 |
| Earnings Per Share Diluted | -2.74 | -2.14 | -1.15 | -0.73 | -0.30 |
| Weighted Average Shares Outstanding | 23.6 Million | 19.4 Million | 18.73 Million | 18.73 Million | 18.73 Million |
| Weighted Average Shares Outstanding (Diluted) | 23.6 Million | 19.4 Million | 18.73 Million | 18.73 Million | 18.73 Million |
| Gross Margin | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - |
| Profit Margin | - | - | - | - | - |
| EBITDA | 4.9 Million | -42.26 Million | - | -6.31 Million | - |
| Earnings Before Tax Margin | - | - | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 80 Thousand | - | - | - |
| Cost of Revenue | - | - | 40 Thousand | - | - | 21 Thousand |
| Gross Profit | - | - | 40 Thousand | - | - | -21 Thousand |
| Operating Expenses | 15.88 Million | 18.29 Million | 18.81 Million | 69.63 Million | 18.18 Million | 16.6 Million |
| Selling, General and Administrative Expenses | 3.73 Million | 3.64 Million | 3.89 Million | - | 3.75 Million | 3.06 Million |
| Research and Development Expenses | 12.14 Million | 14.65 Million | 14.91 Million | - | 14.42 Million | 13.53 Million |
| Other Expenses | 1.44 Million | 1.67 Million | 1.91 Million | - | 1.47 Million | 797 Thousand |
| Cost and Expenses | 15.88 Million | 18.29 Million | 18.81 Million | 69.63 Million | 18.18 Million | 16.6 Million |
| Operating Income | -15.88 Million | -18.29 Million | -18.81 Million | -69.63 Million | -18.18 Million | -16.6 Million |
| Interest Expense | - | - | 716 Thousand | - | - | - |
| Income Tax Expense | -15.88 Million | -18.29 Million | -18.81 Thousand | -69.63 Thousand | -18.18 Thousand | -21 Thousand |
| Earnings before Tax | -14.43 Million | -16.61 Million | -16.89 Million | -64.73 Million | -16.7 Million | -15.8 Million |
| Net Income | -14.43 Million | -16.61 Million | -16.89 Million | -64.73 Million | -16.7 Million | -15.8 Million |
| Earnings Per Share Basic | -0.48 | -0.56 | -0.57 | - | -0.65 | -0.81 |
| Earnings Per Share Diluted | -0.48 | -0.56 | -0.57 | - | -0.65 | -0.81 |
| Weighted Average Shares Outstanding | 29.82 Million | 29.76 Million | 29.73 Million | 23.6 Million | 25.64 Million | 19.49 Million |
| Weighted Average Shares Outstanding (Diluted) | 29.82 Million | 29.76 Million | 29.73 Million | 23.6 Million | 25.64 Million | 19.49 Million |
| Gross Margin | - | - | 0.50 | - | - | - |
| EBIT Margin | - | - | -235.19 | - | - | - |
| Profit Margin | - | - | -211.22 | - | - | - |
| EBITDA | -15.88 Million | -18.29 Million | -18.81 Million | - | -18.18 Million | -16.6 Million |
| Earnings Before Tax Margin | - | - | -235.19 | - | - | - |
098460
STGX
603909
LCUT
KITT
011200